Search
Karyopharm Therapeutics Inc
KPTIAdd to Watchlist
9.600USD
+0.050+0.52%
Close 07/02, 13:00（ET）Quotes delayed by 15 min
175.79MMarket Cap
LossP/E TTM
More Details of Karyopharm Therapeutics Inc Company
Karyopharm Therapeutics Inc. is a commercial-stage pharmaceutical company. The Company is engaged in the discovery, development and commercialization of drugs directed against nuclear export for the treatment of cancer and other diseases. It is developing and commercializing small molecule Selective Inhibitor of Nuclear Export (SINE) compounds that inhibit the nuclear export protein exportin 1 (XPO1). Its lead asset, XPOVIO (selinexor), is marketed in combination with bortezomib and dexamethasone for the treatment of adult patients with multiple myeloma who have received at least one prior therapy. The Company is engaged in evaluating selinexor in certain hematological and solid tumor malignancies, including endometrial cancer, mycosis fungoides (MF) and diffuse large B-cell lymphoma (DLBCL). The Company’s product candidate, eltanexor, is an oral SINE compound like selinexor, that selectively blocks the nuclear export protein XPO1.
Karyopharm Therapeutics Inc Info
Ticker SymbolKPTI
Company nameKaryopharm Therapeutics Inc
IPO dateNov 06, 2013
CEOPaulson (Richard A)
Number of employees279
Security typeOrdinary Share
Fiscal year-endNov 06
Address85 Wells Avenue
CityNEWTON
Stock exchangeNASDAQ OMX - NASDAQ BASIC
CountryUnited States of America
Postal code02459
Phone16176580600
Websitehttps://karyopharm.com/
Ticker SymbolKPTI
IPO dateNov 06, 2013
CEOPaulson (Richard A)
Company Executives of Karyopharm Therapeutics Inc
Name
Name/Position
Position
Shareholding
Change
Mr. Michael Mano, J.D.
Mr. Michael Mano, J.D.
Senior Vice President, General Counsel, Secretary
Senior Vice President, General Counsel, Secretary
85.25K
+0.51%
Mr. Barry E. Greene
Mr. Barry E. Greene
Lead Independent Director
Lead Independent Director
16.41K
+94.47%
Dr. Deepika R. (Deepa) Pakianathan, Ph.D.
Dr. Deepika R. (Deepa) Pakianathan, Ph.D.
Independent Director
Independent Director
15.51K
--
Ms. Christy J. Oliger
Ms. Christy J. Oliger
Independent Director
Independent Director
15.51K
--
Mr. Chen Schor, CPA
Mr. Chen Schor, CPA
Independent Director
Independent Director
15.51K
--
Dr. Zhen Su
Dr. Zhen Su
Independent Director
Independent Director
15.51K
--
Dr. Reshma Rangwala, M.D., Ph.D.
Dr. Reshma Rangwala, M.D., Ph.D.
Executive Vice President, Chief Medical Officer
Executive Vice President, Chief Medical Officer
13.01K
+4.14%
Mr. Stuart Poulton
Mr. Stuart Poulton
Executive Vice President, Chief Development Officer
Executive Vice President, Chief Development Officer
12.50K
+3.94%
Mr. Garen G. Bohlin
Mr. Garen G. Bohlin
Independent Director
Independent Director
--
--
Mr. Richard A. Paulson
Mr. Richard A. Paulson
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
--
--
View more
Name
Name/Position
Position
Shareholding
Change
Mr. Michael Mano, J.D.
Mr. Michael Mano, J.D.
Senior Vice President, General Counsel, Secretary
Senior Vice President, General Counsel, Secretary
85.25K
+0.51%
Mr. Barry E. Greene
Mr. Barry E. Greene
Lead Independent Director
Lead Independent Director
16.41K
+94.47%
Dr. Deepika R. (Deepa) Pakianathan, Ph.D.
Dr. Deepika R. (Deepa) Pakianathan, Ph.D.
Independent Director
Independent Director
15.51K
--
Ms. Christy J. Oliger
Ms. Christy J. Oliger
Independent Director
Independent Director
15.51K
--
Mr. Chen Schor, CPA
Mr. Chen Schor, CPA
Independent Director
Independent Director
15.51K
--
Dr. Zhen Su
Dr. Zhen Su
Independent Director
Independent Director
15.51K
--
FAQs
Who are the top five shareholders of Karyopharm Therapeutics Inc?
The top five shareholders of Karyopharm Therapeutics Inc are: Mr. Michael Mano, J.D.
How many institutions hold shares of Karyopharm Therapeutics Inc (KPTI)?
As of 2026Q1, 236 institutions hold shares of Karyopharm Therapeutics Inc, with a combined market value of approximately 14.10M, accounting for 62.56% of the total shares. Compared to 2025Q4, institutional shareholding has increased by 5055019.00.